Long-Term Efficacy and Safety of Golimumab for Ulcerative Colitis in a Pediatric Inflammatory Bowel Disease Center in Japan
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Golimumab (GLM) is an anti-tumor necrosis factor (TNF)-α antibody preparation known to be less immunogenic than infliximab (IFX) or adalimumab. Few reports on GLM in pediatric patients with ulcerative colitis (UC) are available. This study aimed to review the long-term durability and safety of GLM in a pediatric center. Methods: The medical records of 17 pediatric patients (eight boys and nine girls) who received GLM at the National Center for Child Health and Development were retrospectively reviewed. Results: The median age at GLM initiation was 13.9 (interquartile range 12.0–16.3) years. Fourteen patients had pancolitis, and 11 had severe disease (pediatric ulcerative colitis activity index ≥65). Ten patients were biologic-naïve, and 50% achieved corticosteroid-free remission at week 54. Two patients discontinued prior anti-TNF-α agents because of adverse events during remission. Both showed responses to GLM without unfavorable events through week 54. However, the efficacy of GLM in patients who showed primary nonresponse or loss of response to IFX was limited. Four of the five patients showed non-response at week 54. Patients with severe disease had significantly lower corticosteroid-free remission rate at week 54 than those without severe disease. No severe adverse events were observed during the study period. Conclusion: GLM appears to be safe and useful for pediatric patients with UC. Patients with mild to moderate disease who responded to but had some adverse events with prior biologics may be good candidates for GLM. Its safety and low immunogenicity profile serve as favorable options for selected children with UC.
Abstract
Purpose: Golimumab (GLM) is an anti-tumor necrosis factor (TNF)-α antibody preparation known to be less immunogenic than infliximab (IFX) or adalimumab. Few reports on GLM in pediatric patients with ulcerative colitis (UC) are available. This study aimed to review the long-term durability and safety of GLM in a pediatric center. Methods: The medical records of 17 pediatric patients (eight boys and nine girls) who received GLM at the National Center for Child Health and Development were retrospectively reviewed. Results: The median age at GLM initiation was 13.9 (interquartile range 12.0–16.3) years. Fourteen patients had pancolitis, and 11 had severe disease (pediatric ulcerative colitis activity index ≥65). Ten patients were biologic-naïve, and 50% achieved corticosteroid-free remission at week 54. Two patients discontinued prior anti-TNF-α agents because of adverse events during remission. Both showed responses to GLM without unfavorable events through week 54. However, the efficacy of GLM in patients who showed primary nonresponse or loss of response to IFX was limited. Four of the five patients showed non-response at week 54. Patients with severe disease had significantly lower corticosteroid-free remission rate at week 54 than those without severe disease. No severe adverse events were observed during the study period. Conclusion: GLM appears to be safe and useful for pediatric patients with UC. Patients with mild to moderate disease who responded to but had some adverse events with prior biologics may be good candidates for GLM. Its safety and low immunogenicity profile serve as favorable options for selected children with UC.
참고문헌 (32)
- Benchimol EI, "Epidemiology of pediatric inflammatory bowel disease : a systematic review of international trends", Inflamm Bowel Dis, 17, pp.423~439 (2011)
- "J Crohns Colitis", 2017, 519~526
- Ishige T, "Temporal trend of pediatric inflammatory bowel disease : analysis of national registry data 2004 to 2013 in Japan", J Pediatr Gastroenterol Nutr, 65, pp.80~82 (2017)
- Ungaro R, "Ulcerative colitis", Lancet, 389, pp.1756~1770 (2017)
- D’Haens GR, "The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization : when to start, when to stop, which drug to choose, and how to predict response?", Am J Gastroenterol, 106, pp.199~212 (2011)
- Hyams J, "Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis", Clin Gastroenterol Hepatol, 10, pp.391~399 (2012)[DOI]
- Hyams JS, "Outcome following infliximab therapy in children with ulcerative colitis", Am J Gastroenterol, 105, pp.1430~1436 (2010)
- Aloi M, "Efficacy and safety of adalimumab in pediatric ulcerative colitis : a real-life experience from the SIGENP-IBD registry", J Pediatr Gastroenterol Nutr, 66, pp.920~925 (2018)
- Takeuchi I, "Infliximab for very early-onset inflammatory bowel disease : a tertiary center experience in Japan", J Gastroenterol Hepatol, 35, pp.593~600 (2020)
- Fréling E, "Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease : a 14-year experience", Am J Gastroenterol, 110, pp.1186~1196 (2015)
- Shealy DJ, "Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α", MAbs, 2, pp.428~439 (2010)
- Sandborn WJ, "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis", Gastroenterology, 146, pp.85~95 (2014)
- Sandborn WJ, "Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis", Gastroenterology, 146, pp.96~109 (2014)[DOI]
- Hibi T, "Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis : a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)", J Gastroenterol, 52, pp.1101~1111 (2017)
- Hyams JS, "Subcutaneous golimumab in pediatric ulcerative colitis : pharmacokinetics and clinical benefit", Inflamm Bowel Dis, 23, pp.2227~2237 (2017)
- Xu Y, "Population pharmacokinetics and exposure-response modeling analyses of golimumab in children with moderately to severely active ulcerative colitis", J Clin Pharmacol, 59, pp.590~604 (2019)
- Turner D, "Management of paediatric ulcerative colitis, part 2 : acute severe colitis-an evidence-based consensus guideline from the European Crohn’s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition", J Pediatr Gastroenterol Nutr, 67, pp.292~310 (2018)
- Turner D, "Development, validation, and evaluation of a pediatric ulcerative colitis activity index : a prospective multicenter study", Gastroenterology, 133, pp.423~432 (2007)
- Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease : the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)
- Schroeder KW, "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study", N Engl J Med, 317, pp.1625~1629 (1987)
- Lobatón T, "The Modified Mayo Endoscopic Score(MMES) : a new index for the assessment of extension and severity of endoscopic activity in ulcerative colitis patients", J Crohns Colitis, 9, pp.846~852 (2015)
- Ordás I, "Ulcerative colitis", Lancet, 380, pp.1606~1619 (2012)
- Taxonera C, "Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis", Inflamm Bowel Dis, 23, pp.1394~1402 (2017)
- Pugliese D, "Two-year effectiveness and safety of golimumab in ulcerative colitis : an IG-IBD study", United European Gastroenterol J, 9, pp.102~109 (2021)
- Raine T, "ECCO guidelines on therapeutics in ulcerative colitis : medical treatment", J Crohns Colitis, 16, pp.2~17 (2022)
- Singh S, "Comparative efficacy and speed of onset of action of infliximab vs golimumab in ulcerative colitis", Clin Gastroenterol Hepatol, 18, pp.424~431 (2020)[DOI]
- Adedokun OJ, "Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis : results from phase 2", 3 PURSUIT induction and maintenance studies, 2017, pp.11, 35~46
- Dan Turner, "Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition", Journal of Pediatric Gastroenterology & Nutrition, 67(2), pp.257~291 (2018), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Størdal K, "Pediatric inflammatory bowel disease in southeastern Norway : a five-year follow-up study", Digestion, 70, pp.226~230 (2004)
- Natsuki Ito, "Features and Outcomes of Children with Ulcerative Colitis who Undergo a Diagnostic Change: A Single-Center Experience", Pediatric Gastroenterology, Hepatology & Nutrition, 24(4), pp.357~365 (2021), 대한소아소화기영양학회[DOI]
- Soto Lopes MS, "Paradoxical reaction to golimumab : tumor necrosis factor α inhibitor inducing psoriasis pustulosa", Case Rep Dermatol, 5, pp.326~331 (2013)
- Mateo S, "Psoriasiform exfoliative erythroderma induced by golimumab", Clin Exp Dermatol, 39, pp.813~815 (2014)